Nuvalent
1 follower
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectiv... Read more
Org chart
James Porter
CEO
James Porter
Collapse
Alex Balcom
CFO
Christopher Turner
Chief Medical Officer
Deb Miller
Chief Legal Officer
Darlene Noci
Chief Development Officer
Henry Pelish
SVP, Drug Discovery
Joshua Horan
VP, Chemistry
John Soglia
VP, Translational Development
Jessie Lin
VP, Corporate Strategy & Portfolio Management
Matthew Metivier
VP, Human Resources
Jeffrey Lee
VP, IT
Shannon Dauksis
Senior Director, Program Management
Kristi Byrnes
Senior Director, Quality Assurance
Philip Engel
Director, Cybersecurity & Compliance
José Rios Lizarraga
Associate Director, Formulation Sciences
Wenzhe Fan
Associate Director, Analytical Sciences
